Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of specific types of leukemia, such as Philadelphia chromosome-positive chroni···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：24
Ponatinib is an oral tyrosine kinase inhibitor primarily indicated for the treatment of specific types of leukemia. It is particularly effective for chronic myeloid leukemia (CML) ···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：19
Ponatinib is indicated for the treatment of patients with chronic-phase chronic myeloid leukemia (CML) who have previously received at least two other therapies with inadequate eff···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：16
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI), primarily indicated for the treatment of specific types of leukemia, especially chronic myeloid leukemia (CML) and ···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：19
The price of ponatinib varies depending on the region, specification, purchase channel, and medical insurance policy, and the specific price shall be subject to the actual purchase···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：15
Ponatinib is a targeted therapy indicated for specific types of leukemia, such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), particularly in patients wi···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：21
Ponatinib is an oral targeted drug specifically indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemi···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：17
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for pon···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：19
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was developed by Ariad Pharmaceuticals. The drug has obtained approval from the U.S. Food and Drug Administra···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：16
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ponatinib, for use in combination with ···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：26
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase 3 PhALLCON trial—a randomized, international, open-label, multicenter study—is evaluating the effic···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：28
During treatment with pralsetinib, it is imperative that you inform your healthcare provider of any prescription drugs, over-the-counter medications, vitamins/minerals, herbal prod···【more】
Article source：Captain MedicineRelease date：2026-01-16Recommended：27
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3662024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
